Infusion therapy using the Stennert protocol for sudden sensorineural hearing loss

Sudden sensorineural hearing loss is a sudden loss of hearing originating in the inner ear with no immediately identifiable cause. Any new, sudden reduction in hearing should be assessed promptly by an ear, nose and throat specialist. Only after an examination can it be determined whether this condition is present and which treatment may be appropriate.

What does the Stennert protocol mean?

The historical Stennert protocol combined a corticosteroid preparation with dextran and pentoxifylline as an infusion treatment. A modified Stennert protocol may refer to different combinations of medications. A corticosteroid infusion given today is therefore not automatically equivalent to the original combination protocol. The medications actually used must be determined and explained by a physician on an individual basis.

Benefits and limitations

Historical reports on the Stennert protocol do not establish a proven treatment benefit: spontaneous changes in hearing are possible even without treatment. A controlled study found no relevant additional hearing improvement from dextran and/or pentoxifylline compared with the comparison groups.

The HODOKORT study showed no advantage for the high-dose systemic corticosteroid treatments investigated over the lower comparison dose, but did show more side effects. This study compared different corticosteroid regimens, not corticosteroids with an untreated group. A very high dose or an infusion therefore does not automatically mean a better effect. Restoration of hearing cannot be guaranteed.

Procedure and possible risks

In infusion treatment, a medication is administered through a venous line. The choice of treatment, its duration and monitoring depend on the clinical findings, coexisting conditions and the preparation used. Benefits, alternatives and risks are discussed before treatment.

Corticosteroids can, among other effects, raise blood sugar and blood pressure and affect sleep or mood. Irritation, inflammation and infection can occur at a venous access site. If dextran is used, additional risks such as severe hypersensitivity reactions and fluid overload must be considered. This description is not a dosing guide and does not replace individual medical advice.